Sanofi says it has reached an agreement with Dren Bio that would see it take control of autoimmune disease treatment DR-0201, a bispecific antibody-based myeloid cell engager with the potential to ...

ADEL-Y01, a monoclonal antibody targeting tau protein, is in Phase I trials for Alzheimer's disease, developed by ADEL and licensed to Sanofi. The ADEL-Sanofi agreement is valued at over $1.04 billion ...

Dec 15 (Reuters) - Private biotech company Dren Bio has entered into a strategic collaboration with French drugmaker Sanofi (SASY.PA), opens new tab to develop therapies for autoimmune diseases in a ...

– New collaboration builds on Sanofi’s prior acquisition of DR-0201 and further leverages Dren Bio’s proprietary Targeted Myeloid Engager and Phagocytosis Platform to discover first-in-class ...

Amanda Frances is one of the newest diamond holders on The Real Housewives of Beverly Hills, and things are about to get very interesting. It was announced on Nov. 4 that Amanda, a self-professed ...

Dren Bio, a privately held, clinical-stage biotechnology company developing therapeutics for cancer, autoimmune, and other serious diseases, announced today that it received the 2025 Prix Galien USA ...

Sanofi SNY announced that it signed an agreement with California-based privately held biopharmaceutical company Dren Bio to acquire the latter’s investigational bispecific antibody DR-0201. DR-0201 is ...

Sanofi SA (NASDAQ:SNY) on Thursday agreed to acquire Dren Bio Inc.’s DR-0201, a targeted bispecific myeloid cell engager (MCE). DR-0201 is a CD20-directed bispecific antibody that targets and engages ...

March 20 (Reuters) - Sanofi (SASY.PA), opens new tab on Thursday announced an agreement with biopharmaceutical company Dren Bio for the acquisition of its autoimmune disease treatment DR-0201. The ...

Investing.com -- Sanofi (NASDAQ: SNY), the French healthcare group, revealed on Thursday that it has entered into an agreement to acquire DR-0201, an autoimmune disease treatment from ...

(Reuters) - Sanofi on Thursday announced an agreement with biopharmaceutical company Dren Bio for the acquisition of its autoimmune disease treatment DR-0201. The French healthcare group will acquire ...